Chronic Myelomonocytic Leukemia-2

9 clinical trials · Condition

Sort:Newest first Oldest first

◉ Watch Chronic Myelomonocytic Leukemia-2

Record	Firm	Date
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572)	Newave Pharmaceutical Inc	2022-05-08
Phase I/II Study of Tagraxofusp in Combination With Decitabine for Patients With Myelomonocytic/Myeloproliferative Neoplasm and High Risk Myelodysplastic Syndromes (NCT05038592)	M.D. Anderson Cancer Center	2022-03-04
Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and sAML (NCT05584761)	The First Affiliated Hospital with Nanjing Medical University	2022-03-01
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04734990)	M.D. Anderson Cancer Center	2021-07-07
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms (NCT02756572)	University of Washington	2016-09-22
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (NCT02121418)	University of Washington	2014-06-01
Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (NCT02029950)	National Cancer Institute (NCI)	2013-12-16
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia (NCT01522976)	National Cancer Institute (NCI)	2012-03-01

Track Chronic Myelomonocytic Leukemia-2 automatically

Every clearance here is in the API, with alerts when new ones post.